Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
- PMID: 37803471
- PMCID: PMC10559492
- DOI: 10.1186/s13256-023-04162-y
Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
Abstract
Background: Pembrolizumab as immunotherapy is increasingly used in adjuvant, neoadjuvant, and standalone therapy and has been described as safe. We share an experience of lung erosion post-thoracic surgery with the use of adjuvant pembrolizumab.
Case presentation: A 65-year-old Chinese gentleman with metastatic renal cell carcinoma underwent lung metastasis resection and presented with delayed onset pneumothorax while on adjuvant pembrolizumab. Failure of conservative management warranted repeat surgical intervention, and intraoperative findings showed erosion of staple lines possibly caused by poor healing associated with pembrolizumab.
Conclusion: Adjuvant pembrolizumab may impair wound healing, including stapler line healing. Presentation of delayed pneumothorax in a post-surgical patient undergoing immunotherapy should warrant early surgical intervention.
Keywords: Adjuvant therapy; Case report; Lung cancer; Lung surgery; Pembrolizumab.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures




Similar articles
-
Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.J Thorac Cardiovasc Surg. 2022 Feb;163(2):427-436. doi: 10.1016/j.jtcvs.2021.02.099. Epub 2021 Apr 9. J Thorac Cardiovasc Surg. 2022. PMID: 33985811 Clinical Trial.
-
Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy.Cancer Chemother Pharmacol. 2010 Jul;66(2):409-12. doi: 10.1007/s00280-010-1291-3. Epub 2010 Mar 5. Cancer Chemother Pharmacol. 2010. PMID: 20204363
-
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.Ann Palliat Med. 2022 Sep;11(9):3020-3027. doi: 10.21037/apm-22-960. Ann Palliat Med. 2022. PMID: 36217630
-
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.Expert Rev Anticancer Ther. 2022 Jun;22(6):565-574. doi: 10.1080/14737140.2022.2072300. Epub 2022 Jun 8. Expert Rev Anticancer Ther. 2022. PMID: 35483033 Review.
-
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?Immunotherapy. 2023 Feb;15(2):93-100. doi: 10.2217/imt-2022-0125. Epub 2023 Jan 5. Immunotherapy. 2023. PMID: 36601860 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical